Date: 2016-02-23
Type of information: Development agreement
Compound: gene therapy product optimized for intravitreal administration
Company: 4D Molecular Therapeutics (USA - CA) Choroideremia Research Foundation
Therapeutic area: Rare diseases - Genetic diseases - Ophtalmological diseases (USA - MA)
Type agreement: development
Action mechanism: gene therapy
Disease: choroideremia
Details:
- • On February 23, 2016, 4D Molecular Therapeutics (4DMT), a leader in Adeno-Associated Virus (AAV) gene therapy vector discovery and product development, and the Choroideremia Research Foundation (CRF), a non-profit dedicated to finding a cure for choroideremia, announced a partnership to develop a gene therapy product optimized for intravitreal administration to treat choroideremia.
- Under the terms of the agreement, CRF will provide 4DMT funding to deploy its proprietary AAV vector discovery platform, Therapeutic Vector Evolution, to create and optimize a proprietary AAV vector for intravitreal delivery to the retina. This vector will be the basis of a 4DMT experimental gene therapeutic that will be evaluated and developed by 4DMT in close collaboration with the CRF. Further terms of the agreement were not disclosed.
Financial terms:
Latest news:
Is general: Yes
